Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2031970
Abstract: ABSTRACT Introduction Tebentafusp is a novel bispecific immune mobilizing T cell receptor (TCR)-based agent developed for the treatment of metastatic uveal melanoma, a highly fatal disease with no currently approved treatment options. Recent evidence suggests…
read more here.
Keywords:
melanoma;
uveal melanoma;
metastatic uveal;
efficacy ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2124971
Abstract: ABSTRACT Introduction Metastatic uveal melanoma is associated with poor prognosis and few treatment options. Tebentafusp recently became the first FDA-approved agent for metastatic uveal melanoma. Areas covered In this review, we describe the mechanism of…
read more here.
Keywords:
hla;
uveal melanoma;
metastatic uveal;
treatment ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct223
Abstract: Background: Tebentafusp, a bispecific (gp100 x CD3) ImmTAC, is approved for adult HLA-A*02:01+ patients with unresectable or metastatic uveal melanoma (mUM). In the Ph2 IMCgp100-102 study of pts with previously treated mUM (NCT02570308), tebentafusp demonstrated…
read more here.
Keywords:
tebentafusp;
survival;
metastatic uveal;
previously treated ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359231160140
Abstract: Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific…
read more here.
Keywords:
tebentafusp;
first class;
tebentafusp first;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2023 at "Drugs of today"
DOI: 10.1358/dot.2023.59.3.3542417
Abstract: On January 25, 2022, the U.S. Food and Drug Administration (FDA) approved the use of tebentafusp, a bispecific glycoprotein 100 (gp100) peptide-human leukocyte antigen (HLA)-directed CD3 T-cell activator, for the treatment of HLA-A*02:01-positive adult patients…
read more here.
Keywords:
tebentafusp;
metastatic uveal;
treatment;
drug ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1167791
Abstract: Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100…
read more here.
Keywords:
melanoma;
progression;
metastatic uveal;
uveal melanoma ... See more keywords